Clinical Trials Logo

Nausea clinical trials

View clinical trials related to Nausea.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06395064 Not yet recruiting - Healthy Women Clinical Trials

The Effect of Dimenhydrinate on Postoperative Nausea and Vomiting After Abdominal Hysterectomy: Randomized-controlled Trial

Start date: May 1, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to learn if Dimenhydrinate works to prevent postoperative nausea-vomiting in adult women who undergoing abdominal hysterectomy. The primary question is: Does Dimenhydrinate lower the proportion of postoperative nauseavomiting during the day 1 after surgery. Researcher will compare Dimenhydrinate to a placebo (a-look-alike substance that contains no drug) which will give intravenously when the patient come back to the ward, to see if Dimenhydrinate work to prevent nauseavomiting during the postoperative day1. All participants will receive standard treatment during pre-operative, intra-operative and the immediate post-operative periods. Participants will receive Dimenhydrinate or placebo only one dose after discharge from the recovery room. During the day 1 postoperative, participants will report their symptoms and keep a diary of the number of tmes they use additional anti-emetic drugs.

NCT ID: NCT06394154 Not yet recruiting - Nausea Clinical Trials

Validation of a Mental Health Scale for Young People With Chronic Stomach Symptoms

Start date: May 2024
Phase:
Study type: Observational

This study aims to validate the Alimetry® Gut-Brain Wellbeing Survey- Youth Version (AGBW-Y), a mental health scale developed for patients aged 12-17 years with chronic stomach symptoms.

NCT ID: NCT06382012 Not yet recruiting - Nausea Clinical Trials

Antiemetic Fosaprepitant To Remedy Nausea and Vomiting

AFTR NV RCT
Start date: June 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The study team proposes a randomized, double-blind, RCT to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the standard of care antiemetic ondansetron. Fosaprepitant and its active metabolite aprepitant are a relatively new class of antiemetic that exclusively acts in the central nervous system by blocking neurokinin (NK-1) which is a key signaling molecule in the centrally mediated aspects of the vomiting reflex. Currently, fosaprepitant and aprepitant both have only two United Stated Food and Drug Administration (USFDA) approved indications for nausea and vomiting: chemotherapy-induced and postoperative. Neurokinin inhibitors are highly effective and generally well-tolerated. Therefore, this class of medication may be a more appropriate medication for the millions of patients with nausea and vomiting that seek care in EDs. Intravenous fosaprepitant is converted to the active metabolite aprepitant on the order of minutes and is significantly cheaper to procure at this time. The outcome for the efficacy analysis will be no need for additional medication to treat nausea and vomiting within 2 hours of investigational medication administration. The primary outcome for the tolerability analysis will be the development of any new symptom within 2 hours of medication administration.

NCT ID: NCT06376929 Not yet recruiting - Clinical trials for Postoperative Nausea and Vomiting

Oral Carbohydrates in Pediatric Surgery and Random Blood Glucose Level

Start date: May 2024
Phase: N/A
Study type: Interventional

The correlation between preoperative oral carbohydrate intake and intraoperative random blood sugar and also the effect on postoperative nausea and vomiting.

NCT ID: NCT06357234 Not yet recruiting - Anesthesia Clinical Trials

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

Start date: June 2024
Phase: Phase 2
Study type: Interventional

This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine).

NCT ID: NCT06356623 Not yet recruiting - Liver Cancer Clinical Trials

A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer

Start date: May 5, 2024
Phase:
Study type: Observational

PONV management has been recommended as a necessary part of enhanced recovery protocols during the perioperative period, and PONV risk assessment is, therefore, a necessary first step in determining the number of medications or strategies for prophylaxis and treatment by considering the number of modifiable and non-modifiable risk factors. However, the external validity of two commonly-used PONV prediction models for patients undergoing liver surgery is unsatisfied, and need to be updated for liver cancer populations to better inform personalized perioperative care regime and individualized decision-making in clinical practice.

NCT ID: NCT06333626 Not yet recruiting - Clinical trials for Nausea and Vomiting, Aspiration, Intraoperative

Effects of an Oral Multi-vitamin Carbohydrate Beverage on Intraoperative Nausea and Vomiting

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Nausea and vomiting are common and unpleasant symptoms for pregnant women during cesarean section, which can lead to aspiration, a serious complication that can cause pneumonia. Our study aimed to evaluate the effects of oral multi-vitamin carbohydrate beverage on maternal intraoperative nausea and vomiting by gastric ultrasound.

NCT ID: NCT06331520 Not yet recruiting - Clinical trials for Chemotherapy-induced Nausea and Vomiting

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Start date: May 1, 2024
Phase: Phase 3
Study type: Interventional

The objective of this Prospective, randomized, non inferiority phase III trial is to confirm the efficacy and saftey of dexamethasone-sparing combined with netupitant/palonostron and olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

NCT ID: NCT06288542 Not yet recruiting - Clinical trials for Effect of Dextrose on Postoperative Nausea and Vomiting

Preoperative Dextrose Infusion and Postoperative Nausea and Vomiting

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

This research aims to investigate the efficacy of preoperative intravenous infusion of dextrose 5% during fasting in lowering the incidence and severity of post-operative nausea and vomiting related to laparoscopic gynaecologic procedures

NCT ID: NCT06224894 Not yet recruiting - Cancer Clinical Trials

The Effect of Music Therapy on Nausea, Vomiting and Anxiety Levels in Children

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This study will be conducted with a randomized controlled study model to examine the effect of music therapy on nausea, vomiting and anxiety levels in children diagnosed with oncological cancer receiving cisplatin. The research is planned to be carried out at Dokuz Eylül University Nevvar-Salih İşgören Children's Hospital Pediatric Hematology-Oncology Clinic between December 2023 and December 2024. There is no application for music therapy in the operation of this hospital and clinic.